Redwood Investments adds Bristol-Myers Squibb Co (BMY) to its portfolio

Bristol-Myers Squibb Co (BMY) : Redwood Investments added new position in Bristol-Myers Squibb Co during the most recent quarter end. The investment management firm now holds 293,683 shares of Bristol-Myers Squibb Co which is valued at $20,757,514 , the company said in a statement filed on Apr 20, 2016 with the SEC.Bristol-Myers Squibb Co makes up approximately 2.03% of Redwood Investments’s portfolio.

Bristol-Myers Squibb Co opened for trading at $70.25 and hit $71.07 on the upside on Friday, eventually ending the session at $70.68, with a gain of 0.74% or 0.52 points. The heightened volatility saw the trading volume jump to 58,03,996 shares. Company has a market cap of $117,997 M.

Other Hedge Funds, Including , Ronna Sue Cohen reduced its stake in BMY by selling 39,866 shares or 55.56% in the most recent quarter. The Hedge Fund company now holds 31,890 shares of BMY which is valued at $2,253,985. Bristol-Myers Squibb Co makes up approx 1.89% of Ronna Sue Cohen’s portfolio. Round Table Services added BMY to its portfolio by purchasing 3,226 company shares during the most recent quarter which is valued at $219,529. Bristol-Myers Squibb Co makes up approx 0.14% of Round Table Services’s portfolio.Franklin Street Advisors Inc Nc boosted its stake in BMY in the latest quarter, The investment management firm added 5,142 additional shares and now holds a total of 116,949 shares of Bristol-Myers Squibb Co which is valued at $7,958,379. Bristol-Myers Squibb Co makes up approx 1.55% of Franklin Street Advisors Inc Nc’s portfolio. Integrated Investment Consultants added BMY to its portfolio by purchasing 4,000 company shares during the most recent quarter which is valued at $272,200. Bristol-Myers Squibb Co makes up approx 0.15% of Integrated Investment Consultants’s portfolio.Creative Planning reduced its stake in BMY by selling 2,475 shares or 0.9% in the most recent quarter. The Hedge Fund company now holds 272,975 shares of BMY which is valued at $18,010,891. Bristol-Myers Squibb Co makes up approx 0.14% of Creative Planning’s portfolio.

On the company’s financial health, Bristol-Myers Squibb Co reported $0.38 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $0.28. The company had revenue of $4287.00 million for the quarter, compared to analysts expectations of $4154.19 million. The company’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.46 EPS.

Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Societe Generale Initiated Bristol-Myers Squibb Co on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $48.Bristol-Myers Squibb Co was Upgraded by Berenberg to ” Buy” on Jan 22, 2016.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Leave a Reply

Bristol-Myers Squibb Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bristol-Myers Squibb Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.